[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.147.238.168. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Other Articles
September 2, 1961

Development of a Purified Poliomyelitis Virus Vaccine

Author Affiliations

West Point, Pa.

From the Division of Virus and Tissue Culture Research, Merck Institute for Therapeutic Research. Dr. Charney is now associated with the South Jersey Medical Research Foundation, Camden, N.J.

JAMA. 1961;177(9):591-595. doi:10.1001/jama.1961.03040350001001
Abstract

Improvements to be desired in commercial Salk poliomyelitis vaccine are the elimination of lot-to-lot variations in potency, increase in mean vaccine potency, and elimination of foreign antigens, particularly host (monkey kidney) antigen. These objectives have been achieved by the inactivation of purified, concentrated poliomyelitis virus to give a vaccine containing standard optimal quantities of poliomyelitis antigen which are essentially free from nonviral antigens. The relatively avirulent Parker type I poliovirus was substituted for the highly neurovirulent type I Mahoney strain. Removal of the monkey kidney antigen minimized the hazard of inducing allergic or auto-immune reactions. The preparation and testing of this vaccine are described.

×